COO — The Cooper Companies, Inc. stock price, charts and financials

NASDAQ·Healthcare·Medical - Instruments & Supplies·USA

Latest market price

55.29

+1.51+2.81%

Overview Short InterestFilings

COOQT35The Cooper Companies, Inc.·NASDAQ

Overview Short InterestFilings

55.29+2.81%

News

Up 2.8% — Top S&P500 movers in Friday's session (ChartMill).

Medium confidence

Loading chart...

Signal & projected range

Insider buying clusterHistorical pattern — not a prediction

Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)

Horizon

Unlock the projected rangeSee where this setup landed historically — with Premium.

Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

AVTR-2.14%$15.52 RGEN-0.73%$176.89 BAX-0.96%$22.80 ATR-0.84%$124.44 SOLV+1.50%$88.84 BLCO+0.48%$16.85 STVN-4.28%$21.70 TFX-0.85%$124.52

Snapshot

Index	S&P 500	P/E	18.87	EPS (ttm)	2.93	Insider Own	0.63%	Shs Outstand	195.03M	Perf Week	2.56%

Market Cap	10.78B	Forward P/E	11.75	EPS next Y	4.71	Insider Trans	2.81%	Shs Float	193.67M	Perf Month	-27.94%

Enterprise Value	13.17B	PEG	2.01	EPS next Q	1.08	Inst Own	-	Short Float	4.53%	Perf Quarter	-16.11%

Income	571.00M	P/S	2.55	EPS this Y	55.03%	Inst Trans	-	Short Ratio	3.42	Perf Half Y	-21.81%

Sales	4.24B	P/B	1.29	EPS next Y	3.60%	ROA	4.50%	Short Interest	8.78M	Perf YTD	-32.54%

Book/sh	42.70	P/C	69.57	EPS next 5Y	9.41%	ROE	6.88%	52W High	89.83 -38.45%	Perf Year	-14.04%

Cash/sh	0.79	P/FCF	116.05	EPS past 3/5Y	-1.22% -17.22%	ROIC	4.76%	52W Low	51.01 8.39%	Perf 3Y	-35.83%

Dividend Est.	0.01 (0.01%)	EV/EBITDA	14.48	Sales past 3/5Y	7.35% 10.98%	Gross Margin	63.64%	Volatility	3.07% 2.82%	Perf 5Y	-51.00%

Dividend TTM	-	EV/Sales	3.11	EPS Y/Y TTM	49.49%	Oper. Margin	12.85%	ATR (14)	2.39	Perf 10Y	18.42%

Dividend Ex-Date	Jul 26, 2023	Quick Ratio	0.73	Sales Y/Y TTM	8.78%	Profit Margin	13.46%	RSI (14)	25.60	Recom	2.54

Dividend Gr. 3/5Y	0.00% 0.00%	Current Ratio	1.22	EPS Q/Q	4.55%	SMA20	-14.91%	Beta	0.81	Target Price	65.75

Payout	0.00%	Debt/Eq	0.34	Sales Q/Q	0.57%	SMA50	-20.95%	Rel Volume	3.04	Prev Close	53.78

Employees	15,000	LT Debt/Eq	0.33	Earnings	Dec 03	SMA200	-23.78%	Avg Volume	2.89M	Price	55.29

IPO Date	Jan 21, 1983	Option/Short	Yes / Yes	EPS/Sales Surpr.	2.34% -2.93%	Net Debt/EBITDA	2.63	Volume	8,794,225	Change	2.81%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Sep-10-26	Reiterated	Stifel Nicolaus	Buy	$95 → $70
Sep-10-26	Reiterated	Robert W. Baird		$98 → $61
Sep-10-26	Downgrade	William Blair	Outperform → Market Perform
Sep-10-26	Downgrade	B of A Securities	Buy → Neutral
Sep-10-26	Downgrade	Baird	Outperform → Neutral
Sep-10-26	Downgrade	Piper Sandler	Overweight → Neutral	$86 → $59
Sep-10-26	Reiterated	Wells Fargo	Equal Weight	$66 → $61
Sep-10-26	Reiterated	Needham	Buy	$86 → $73
Sep-10-26	Reiterated	UBS	Neutral	$66
Jun-05-26	Reiterated	Wells Fargo	Equal Weight	$66

Latest News· Times ET

Sep-18-26

Sep-18-2603:05PM

Top S&P500 movers in Friday's sessionChartMill

06:07AM

Cooper Companies (COO) Securities Investigation Notice - Levi & Korsinskyprnewswire.com

04:50AM

Jana urges Cooper to replace CEO, explore asset sales after performance setbacksreuters.com

03:37AM

Activist Calls for Cooper Cos. to Seek New CEO.barrons.com

Sep-17-26

Sep-17-2603:11PM

INVESTOR ALERT: Pomerantz Law Firm Investigates ClaimsOn Behalf of Investors of Corning Incorporated - COOprnewswire.com

03:00PM

Jana Partners Pushes Contact-Lens Maker Cooper to Replace Its CEOwsj.com

06:00AM

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of The Cooper Companies, Inc. - COOprnewswire.com

05:43AM

The Cooper Companies (NASDAQ: COO) Scrutinized Over U.S. Channel Inventory Reductions Driving Stock Sharply Lower -- HBSSglobenewswire.com

Sep-16-26

Sep-16-2601:09PM

COOPERCOMPANIES ALERT: Bragar Eagel & Squire, P.C. is Investigating The Cooper Companies, Inc. on Behalf of CooperCompanies Stockholders and Encourages Investors to Contact the Firmglobenewswire.com

07:24AM

Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving Cooper Companies (COO)businesswire.com

Sep-15-26

Sep-15-2611:33AM

COOPER COMPANIES, INC. INVESTIGATION: COO Securities Investors Encouraged to Contact Kirby McInerney LLP About Their Rightsglobenewswire.com

06:09AM

COO Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Cooper Companies (COO)businesswire.com

05:00AM

Early Anthropic hire, former METR COO have found a way to rein in rogue AI agentstechcrunch.com

04:30AM

Cooper Companies: A Little More Compelling At This Priceseekingalpha.com

Sep-14-26

Sep-14-2603:00PM

Rosen Law Firm Encourages The Cooper Companies, Inc. Investors to Inquire About Securities Class Action Investigation - COObusinesswire.com

Company

The Cooper Companies, Inc. (COO) operates as a global medical device firm, primarily focused on developing, producing, and distributing products through two distinct business units: CooperVision and CooperSurgical. CooperVision specializes in contact lenses. Their product range includes spherical lenses for common vision issues like nearsightedness and farsightedness, as well as advanced lenses such as toric for astigmatism, multifocal for presbyopia, and specialized options addressing myopia, dry eyes, and eye fatigue. These vision correction solutions are available across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region. Meanwhile, CooperSurgical is dedicated to women's and family health, providing a wide array of medical devices, fertility treatments, genetic testing, diagnostic tools, and contraceptives to healthcare providers and patients globally. This segment's offerings encompass various surgical and office-based products like PARAGARD (an IUD), uterine manipulators, retractors, and closure devices. It also delivers comprehensive fertility services, including specialized consumables, equipment, embryo services, and preimplantation genetic screening. Established in 1958, The Cooper Companies, Inc. is headquartered in San Ramon, California.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	TTM —	FY 2025 10/31/2025	FY 2024 10/31/2024	FY 2023 10/31/2023	FY 2022 10/31/2022	FY 2021 10/31/2021	FY 2020 10/31/2020	FY 2019 10/31/2019	FY 2018 10/31/2018
Total Revenue	4,237	4,092	3,895	—	—	—	—	—	—
Cost of Goods Sold Incl. D&A	1,540	1,610	1,300	—	—	—	—	—	—
Gross Profit	2,696	2,483	2,596	—	—	—	—	—	—
Selling, General and Administrative Excl. Other	1,886	1,628	1,534	—	—	—	—	—	—
Research and Development	170	172	155	—	—	—	—	—	—
Other Operating Expense	96	0	201	—	—	—	—	—	—
Operating Income	544	683	706	—	—	—	—	—	—
Interest Expense	94	100	114	—	—	—	—	—	—
Unusual Expense	—	—	—	—	—	—	—	—	—
Non-Operating Income (Expense)	13	-16	-9	—	—	—	—	—	—
Net Income Before Taxes	463	567	582	—	—	—	—	—	—
Income Taxes	-108	192	190	—	—	—	—	—	—
Consolidated Net Income	571	375	392	—	—	—	—	—	—
Net Income From Continuing Operations	571	375	392	—	—	—	—	—	—
Net Income	571	375	392	—	—	—	—	—	—
EPS (Recurring)	2.93	1.88	1.97	—	—	—	—	—	—
EPS (Basic, Before Extraordinaries)	2.93	1.88	1.97	—	—	—	—	—	—
EPS (Diluted)	2.93	1.87	1.96	—	—	—	—	—	—
EBITDA	910	1,053	1,072	—	—	—	—	—	—
Other After Tax Adjustments	—	—	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—	—	—
Price To Earnings Ratio	18.87	37.39	53.41	—	—	—	—	—	—
Price To Sales Ratio	2.52	3.42	5.35	—	—	—	—	—	—
Gross Margin	63.63	60.68	66.65	—	—	—	—	—	—
Operating Margin	12.84	16.69	18.13	—	—	—	—	—	—
Net Margin	13.48	9.16	10.06	—	—	—	—	—	—
Shares Outstanding	193	200	199	—	—	—	—	—	—
Market Capitalization	10,671	13,982	20,831	—	—	—	—	—	—
Operating Lease Expense	—	—	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Unlock with Premium

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Kurzius Lawrence Erik	Director	Sep 16 '26	Buy	54.93	10,000	549,320	31,099	Sep 17
Rosebrough Walter M Jr	Director	Sep 14 '26	Buy	54.29	3,000	162,870	20,000	Sep 15
Kurzius Lawrence Erik	Director	Sep 14 '26	Buy	53.91	10,000	539,150	21,099	Sep 15
Rosebrough Walter M Jr	Director	Sep 11 '26	Buy	54.11	7,000	378,770	17,000	Sep 15
Keel Paul A	Director	Sep 11 '26	Buy	53.18	4,701	250,000	4,701	Sep 15
Rosebrough Walter M Jr	Director	Apr 01 '26	Option Exercise	0.00	832	0	832	Apr 21
MADDEN TERESA S	Director	Apr 01 '26	Option Exercise	0.00	3,322	0	15,679	Apr 06
Lucchese Cynthia L	Director	Apr 01 '26	Option Exercise	0.00	3,322	0	12,767	Apr 06
Kurzius Lawrence Erik	Director	Apr 01 '26	Option Exercise	0.00	3,322	0	11,099	Apr 06
WEISS ROBERT S	Director	Apr 01 '26	Option Exercise	0.00	3,654	0	292,599	Apr 06
Rivas Maria	Director	Apr 01 '26	Option Exercise	0.00	3,322	0	3,322	Apr 06
Jay Colleen	Director	Apr 01 '26	Option Exercise	0.00	3,322	0	39,907	Apr 06
Carbone Barbara	Director	Apr 01 '26	Option Exercise	0.00	3,050	0	3,050	Apr 06
Jay Colleen	Director	Jan 12 '26	Option Exercise	39.40	7,064	278,322	36,585	Jan 14
McBride Daniel G	EVP & Chief Operating Officer	Jan 08 '26	Option Exercise	0.00	12,887	0	76,007	Jan 12

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.